131,122 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Purchased by Second Line Capital LLC

Second Line Capital LLC purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 131,122 shares of the company's stock, valued at approximately $1,529,000. Second Line Capital LLC owned approximately 0.13% of Intellia Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. ARK Investment Management LLC increased its holdings in shares of Intellia Therapeutics by 2.3% during the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after buying an additional 280,946 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Intellia Therapeutics by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock worth $118,816,000 after buying an additional 562,249 shares in the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth approximately $43,177,000. Geode Capital Management LLC increased its holdings in shares of Intellia Therapeutics by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company's stock worth $27,865,000 after buying an additional 45,930 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Intellia Therapeutics by 36.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,976,212 shares of the company's stock worth $23,042,000 after buying an additional 528,962 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on NTLA shares. Chardan Capital reaffirmed a "buy" rating and set a $68.00 price objective on shares of Intellia Therapeutics in a report on Friday, May 9th. Citigroup decreased their price target on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Wells Fargo & Company decreased their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Finally, Guggenheim decreased their price target on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $36.90.

Intellia Therapeutics Trading Up 1.4%

Shares of Intellia Therapeutics stock traded up $0.13 during trading on Thursday, hitting $9.33. 1,194,650 shares of the stock were exchanged, compared to its average volume of 3,415,875. The stock has a market capitalization of $965.91 million, a price-to-earnings ratio of -1.71 and a beta of 2.33. The company has a fifty day moving average price of $7.99 and a 200-day moving average price of $10.67. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. The firm's revenue for the quarter was down 42.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.12) earnings per share. Equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.